All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
335 trials found
Drug [desc] |
NCT# |
||
|---|---|---|---|
| Ziftomenib + Imatinib | A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | 1 |
|
| XmAb18087 | A Study of XmAb®18087 in Subjects With NET and GIST | 1 |
|
| XL820 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | 2 |
|
| XL820 | Study of XL820 in Adults With Solid Tumors | 1 |
|
| XL820 | Study of XL820 Given Orally Daily to Subjects With Solid Tumors | 1 |
|
| XL765 | Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors | 1 |
|
| XL228 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | 1 |
|
| XL147 | Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors | 1 |
|
| Vorinostat + Bortezomib | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors | 1 |
|
| Vemurafenib | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé) | 2 |
|
| Vandetanib | Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | 2 |
|
| Trametinib + Palbociclib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | 1 |
|
| THE-630 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | 1/2 |
|
| Temozolomide | Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors | 2 |
|
| Temozolomide | Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor | 2 |
|
| Temozolomide | The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST) | 2 |
|
| TAS-116 | Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial | 2 |
|
| Sutent (Sunitinib, SU11248) + Sirolimus (Rapamycin, Rapamune) | A Study of the Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy | 1 |
|
| Surgery | Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor | 2 |
|
| Surgery | Liver Transplantation for Unresectable GIST Liver Metastases (TRANSGIST) | 0 |
|
| Surgery | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis | ||
| Sunitinib or Sorafenib | Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST) | ||
| Sunitinib or Imatinib | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib) | 3 |
|
| Sunitinib + TH-302 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma and Gastrointestinal Stromal Tumors (TH-CR-410) | 1 |
|
| Sunitinib + Regorafenib | A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial | 1 |
|
| Sunitinib + Radiation | Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer | 2 |
|
| Sunitinib + CP-751,871 | Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors | 1 |
|
| Sunitinib | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent | 4 |
|
| Sunitinib | Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST) | 4 |
|
| Sunitinib | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients | 4 |
|
| Sunitinib | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumors (Gist) | 3 |
|
| Sunitinib | SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor | 3 |
|
| Sunitinib | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | 3 |
|
| Sunitinib | A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | 3 |
|
| Sunitinib | Study Of SU011248 Administered In A Daily Regimen In Patients With Gastrointestinal Stromal Tumor | 2 |
|
| Sunitinib | Evaluation of Patients With Bulky GIST Using Sunitinib | 2 |
|
| Sunitinib | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | 2 |
|
| Sunitinib | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) | 1 |
|
| SU5416 | SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas | 2 |
|
| STA-9090 | A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) | 2 |